Company news

Chimeric Therapeutics Limited news in 2024

Chimeric Therapeutics Limited's news releases, calls and decks from 2024, newest first.

View company

Phase 1B CHM CORE-NK trial advances to newly diagnosed AML

December 15, 2024

Chimeric receives $4.17m R&D tax incentive

November 27, 2024

AGM Presentation and CEO Appointment

November 11, 2024

Reinstatement to Official Quotation

October 21, 2024

$5 million Placement to progress CHM CDH17 trial

October 21, 2024

AML patient achieves Complete Response in CHM CORE-NK trial

October 6, 2024

Appendix 4E and Preliminary Final Report

August 30, 2024

First patient dosed in Phase 1/2 trial of CHM CDH17

August 28, 2024

First patient enrolled in CHM CDH17 Phase 1/2 clinical trial

July 22, 2024

Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA

June 4, 2024

Chimeric opens CHM CDH17 Phase 1/2 trial

May 22, 2024

CHM CDH17 Phase 1/2 clinical trial approved for initiation

May 19, 2024

Resignation of CEO and Managing Director

May 1, 2024

Clinical milestones for 2024 & 2023 successes highlighted

March 13, 2024

Half Yearly Report and Accounts

February 28, 2024

1st patient treated in ADVENT-AML Phase 1b clinical trial

February 7, 2024

Placement of Entitlement Offer Shortfall

January 18, 2024

ADVENT-AML Phase 1B clinical trial open to enrolment

January 14, 2024

Chimeric receives $7.36M R&D tax incentive

January 9, 2024

Decks in 2024